Double maintains 1 strategies that include SAGE - SAGE Therapeutics, Inc.
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CREG | -14.43% | $5.91M | -76.05% | 0.00% |
| OMCL | -14.18% | $1.39B | +11.21% | 0.00% |
| NXTC | -11.40% | $13.13M | -70.65% | 0.00% |
| CASI | -11.03% | $22.15M | -77.52% | 0.00% |
| K | -10.87% | $27.64B | +40.17% | 2.86% |
| SRPT | -10.81% | $1.87B | -87.47% | 0.00% |
| VHC | -7.69% | $69.05M | +176.10% | 0.00% |
| EXEL | -7.01% | $12.32B | +100.31% | 0.00% |
| IDA | -6.78% | $6.37B | +24.17% | 2.90% |
| HUSA | -6.53% | $20.99M | -8.33% | 0.00% |
| CBOE | -6.22% | $24.55B | +38.09% | 1.08% |
| VSA | -5.97% | $8.59M | -17.17% | 0.00% |
| EIX | -5.93% | $19.73B | -30.95% | 6.42% |
| QXO | -5.67% | $14.37B | -48.66% | 0.00% |
| T | -5.39% | $198.74B | +46.45% | 5.06% |
| INSP | -5.12% | $4.11B | +2.67% | 0.00% |
| LITB | -5.02% | $24.26M | -71.62% | 0.00% |
| CCEC | -5.01% | $1.02B | +3.91% | 2.48% |
| CMS | -4.16% | $21.10B | +16.29% | 3.01% |
| STG | -4.14% | $38.79M | -3.01% | 0.00% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| OPCH | 48.06% | $4.99B | +5.28% | 0.00% |
| IMMR | 39.93% | $255.28M | -23.57% | 1.14% |
| ILPT | 39.67% | $356.51M | +32.43% | 0.75% |
| AMD | 39.32% | $233.74B | -20.77% | 0.00% |
| HHH | 39.30% | $3.58B | +7.00% | 0.00% |
| AVNS | 39.23% | $566.95M | -42.12% | 0.00% |
| FTV | 38.41% | $17.99B | -6.03% | 0.61% |
| BXMT | 38.23% | $3.45B | +6.12% | 9.42% |
| BLKB | 38.21% | $3.19B | -14.55% | 0.00% |
| LAB | 38.05% | $512.76M | -31.12% | 0.00% |
| OFLX | 37.77% | $366.93M | -29.62% | 3.81% |
| LXU | 37.61% | $600.90M | +7.18% | 0.00% |
| KRC | 37.59% | $4.31B | +6.67% | 5.94% |
| QRVO | 37.39% | $8.39B | -26.28% | 0.00% |
| BBIO | 36.62% | $8.79B | +72.07% | 0.00% |
| IAC | 36.61% | $3.33B | +3.54% | 0.00% |
| ROP | 36.53% | $59.11B | -1.10% | 0.59% |
| STNE | 36.38% | $4.35B | +19.37% | 0.00% |
| AUDC | 36.29% | $286.71M | -11.94% | 3.75% |
| CERS | 36.19% | $296.30M | -26.54% | 0.00% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VEGI | 40.61% | $104.26M | 0.39% |
| MOO | 39.02% | $657.57M | 0.55% |
| AMDY | 37.60% | $163.74M | 1.23% |
| XT | 37.59% | $3.43B | 0.46% |
| PBE | 37.49% | $226.91M | 0.58% |
| ISRA | 37.14% | $114.75M | 0.59% |
| SLX | 36.85% | $78.66M | 0.56% |
| KJAN | 36.79% | $279.50M | 0.79% |
| FV | 36.65% | $3.65B | 0.87% |
| USVM | 36.62% | $969.39M | 0.3% |
| IWM | 36.53% | $65.64B | 0.19% |
| GSSC | 36.34% | $591.16M | 0.2% |
| VTWO | 36.20% | $12.65B | 0.07% |
| IWC | 36.13% | $840.86M | 0.6% |
| IWO | 35.99% | $11.77B | 0.24% |
| DRIV | 35.72% | $310.54M | 0.68% |
| SCHA | 35.71% | $17.61B | 0.04% |
| DFAS | 35.71% | $10.54B | 0.27% |
| IWN | 35.66% | $11.34B | 0.24% |
| ESPO | 35.66% | $387.14M | 0.56% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| OS | 0.06% | $4.55B | +29.00% | 0.00% |
| VZ | -0.17% | $177.21B | +1.77% | 8.05% |
| FATBB | 0.18% | $47.76M | -9.82% | 10.45% |
| NINE | 0.31% | $37.70M | -46.37% | 0.00% |
| SO | -0.35% | $102.50B | +16.78% | 3.13% |
| LPTH | 0.36% | $125.69M | +128.91% | 0.00% |
| PSQH | -0.45% | $105.65M | -40.36% | 0.00% |
| CANG | -0.48% | $362.71M | +175.00% | 0.00% |
| KMB | -0.52% | $43.78B | -6.43% | 3.77% |
| PPL | 0.56% | $25.38B | +21.65% | 3.11% |
| CMTL | 0.60% | $84.66M | -18.18% | 0.00% |
| PULM | 0.61% | $23.52M | +206.67% | 0.00% |
| MO | 0.61% | $98.62B | +24.36% | 7.00% |
| LUMN | 0.71% | $4.63B | +288.79% | 0.00% |
| PRPO | -0.72% | $23.73M | +229.04% | 0.00% |
| MNOV | -0.76% | $62.29M | -8.63% | 0.00% |
| TRUG | 0.79% | $5.41M | -89.51% | 0.00% |
| NRDS | 0.86% | $841.25M | -22.88% | 0.00% |
| ABT | -0.94% | $232.44B | +28.24% | 1.71% |
| AQB | -1.00% | $3.04M | -56.34% | 0.00% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| UNG | -0.02% | $375.27M | 1.06% |
| GOVZ | -0.10% | $265.96M | 0.1% |
| UUP | -0.13% | $196.45M | 0.77% |
| AGGH | 0.14% | $321.29M | 0.29% |
| VGIT | 0.29% | $31.63B | 0.04% |
| TBIL | -0.31% | $5.76B | 0.15% |
| BSMW | -0.32% | $107.49M | 0.18% |
| DBE | 0.36% | $54.61M | 0.77% |
| ZROZ | 0.41% | $1.45B | 0.15% |
| STXT | -0.47% | $128.32M | 0.49% |
| IBDQ | -0.49% | $2.96B | 0.1% |
| SPTI | 0.50% | $8.68B | 0.03% |
| LDUR | -0.63% | $922.12M | 0.5% |
| USL | 0.67% | $43.93M | 0.85% |
| TYA | 0.71% | $147.35M | 0.15% |
| UTEN | 0.71% | $210.57M | 0.15% |
| FXE | 0.75% | $588.06M | 0.4% |
| UDN | -0.77% | $147.46M | 0.78% |
| IEI | -0.78% | $15.53B | 0.15% |
| IEF | 0.82% | $34.50B | 0.15% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VIXY | -32.10% | $184.73M | 0.85% |
| BTAL | -26.47% | $315.93M | 1.43% |
| TAIL | -25.83% | $94.86M | 0.59% |
| IBTF | -10.44% | $1.98B | 0.07% |
| IVOL | -8.45% | $342.69M | 1.02% |
| CLIP | -8.35% | $1.55B | 0.07% |
| SPTS | -7.84% | $5.77B | 0.03% |
| FXY | -6.35% | $802.69M | 0.4% |
| GBIL | -5.69% | $6.36B | 0.12% |
| TBLL | -5.47% | $2.12B | 0.08% |
| XBIL | -4.77% | $784.60M | 0.15% |
| BIL | -4.55% | $41.93B | 0.1356% |
| IBTG | -4.09% | $1.92B | 0.07% |
| SHYM | -3.83% | $355.86M | 0.35% |
| FLMI | -3.52% | $735.37M | 0.3% |
| USDU | -3.23% | $129.80M | 0.5% |
| ULST | -3.05% | $592.38M | 0.2% |
| IBTH | -3.02% | $1.62B | 0.07% |
| FTSD | -2.77% | $233.11M | 0.25% |
| STPZ | -2.76% | $443.27M | 0.2% |
Current Value
$9.191 Year Return
Current Value
$9.191 Year Return
Yahoo
Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal.
Yahoo
Health care stocks advanced late Tuesday afternoon, with the NYSE Health Care Index and the Health C
Yahoo
Health care stocks rose Tuesday afternoon, with the NYSE Health Care Index up 1.2% and the Health Ca
Yahoo
FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the appointment of Anne Marie Cook, J.D., as Chief Legal Officer and Corporate Secretary. Ms. Cook is an accomplished pharmaceutical legal executive with a proven track record advising pharmaceutical companies and broad expertise in corporate governance, commer
Finnhub
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC are investigating the proposed sale of Sage Therapeutics, Inc. to Supernus Pharmaceuticals,...
Yahoo
H.C. Wainwright analyst Douglas Tsao says that while a takeover of Sage Therapeutics (SAGE) comes as no surprise, but a deal with Supernus (SUPN) is unexpected, and “leaves open the door for additional competition.” The merger agreement includes a “modest” breakup fee of just $22.4M payable to Supernus in the event Sage accepts a superior offer, the analyst tells investors in a research note. The firm believes the “relatively modest breakup fee” would not dissuade Biogen (BIIB) from pursuing a b
